Indian Journal of Critical Care Medicine

Register      Login

SEARCH WITHIN CONTENT

FIND ARTICLE

Volume / Issue

Online First

Archive
Volume  28 (2024)
Volume  27 (2023)
Volume  26 (2022)
Volume  25 (2021)
Volume  24 (2020)
Volume  23 (2019)
Volume  22 (2018)
Volume  21 (2017)
Volume  20 (2016)
Volume  19 (2015)
Volume  18 (2014)
Volume  17 (2013)
Volume  16 (2012)
Volume  15 (2011)
Volume  14 (2010)
Volume  13 (2009)
Volume  12 (2008)
Volume  11 (2007)
Volume  10 (2006)
Volume  9 (2005)
Volume  8 (2004)
Related articles

VOLUME 28 , ISSUE 1 ( January, 2024 ) > List of Articles

BRIEF RESEARCH COMMUNICATION

Effect of Aviptadil, a Novel Therapy, on Clinical Outcomes of Patients with Viral-related Severe ARDS: A Retrospective Observational Study

Supriya Sampley, Deepak Bhasin, Kavita Sekhri, Harpal Singh, Onkar Gupta

Keywords : Aviptadil, Viral acute respiratory distress syndrome, Viral pneumonia

Citation Information : Sampley S, Bhasin D, Sekhri K, Singh H, Gupta O. Effect of Aviptadil, a Novel Therapy, on Clinical Outcomes of Patients with Viral-related Severe ARDS: A Retrospective Observational Study. Indian J Crit Care Med 2024; 28 (1):70-74.

DOI: 10.5005/jp-journals-10071-24594

License: CC BY-NC 4.0

Published Online: 30-12-2023

Copyright Statement:  Copyright © 2024; The Author(s).


Abstract

Background: Dealing with life-threatening viral acute respiratory distress syndrome (ARDS) has always been challenging and with the recent COVID pandemic experience, there is still the need of newer therapies to alleviate mortality. Aviptadil, has shown significant beneficial results in COVID. We share our experience with this molecule by doing a retrospective study to evaluate the effect of this drug on clinical outcomes in viral-related ARDS patients. Materials and methods: In this study, all patients with severe viral-related ARDS received Aviptadil along with the conventional treatment. The oxygen saturation, SpO2/FiO2 (ratio of pulse oximetric saturation to fractional inspired oxygen) (S/F) ratio and PaO2/FiO2 (ratio of arterial oxygen partial pressure to fractional inspired oxygen) (P/F) ratio, before and after completion of the drug were studied. Radiological clearance and time for complete recovery from respiratory failure was noted. All variables pre- and postadministration of the drug were compared. Results: A total of 68 patients with viral pneumonias were admitted to intensive care unit (ICU) and only 6 patients had severe ARDS, who received Aviptadil. The mean oxygen saturation significantly improved from 87.86% before the first Aviptadil dose to 93.43% post 3 days of infusion. Similarly, improvement was seen in PaO2 values from 54.32 to 68.4 posttherapy (p-value < 0.004). SpO2/FiO2 (ratio of pulse oximetric saturation to fractional inspired oxygen) ratio hiked from 149 to 336 at the end of the 3 days infusion (p-value < 0.003). RALE scoring system was used for radiological clearance and the mean change in the score was from 6.42 to 2.5 (p-value 0.00). The average length of stay in the ICU was 12.14 days. No adverse effects were noted. Conclusion: Aviptadil has shown to improve the clinical outcomes in patients with severe viral-related ARDS without any adverse effects.

PDF Share
  1. Brun-Buisson C, Minelli C, Bertolini G, Brazzi L, Pimentel J, Lewandowski K, et al. Epidemiology and outcome of acute lung injury in European intensive care units. Results from the ALIVE study. Intensive Care Med 2004;30(1):51–61. DOI: 10.1007/s00134-003-2022-6.
  2. Gordon D, Rubenfeld MD, Ellen Caldwell MS, Eve Peabody BA, Jim Weaver RRT, Diane P, et al. Incidence and outcomes of acute lung injury. Engl J Med 2005;353:1685–1693. DOI: 10.1056/NEJMoa050333.
  3. Orphan Drug Designations and Approvals: Vasoactive Intestinal Peptide: Acute Respiratory Distress Syndrome, USFDA 2001. Available at: https://www.accessdata.fda.gov/scrpits/opdliting/oopd/listResult.cfm.
  4. CEO Update: Nation of Georgia Emergency Use Authorization. Oct 25, 2021. Available on https://www.nrxpharma.com/ceo-update-nation-of-georgia-emergency-use-authoristaion.
  5. Recommendations of the SEC meeting to examine COVID -19 related proposal under accelerated approval process made in its 218th meeting held on 05/04/2022 at CDSCO, HQ Ne Delhi. Available at: https://cdsco.gov.in/opencmd/opencms/system/modules/CDSCO.WEB/common_download.jsp?num_id_pk+MTY3NA==.
  6. Webster RG, Govorkova E A. Continuing challenges in influenza. Ann N Y Acad Sci 2014;1323:115–139. DOI: 10.1111/nyas.12462.
  7. Saunders-Hastings PR, Krewski D. Reviewing the history of pandemic influenza: Understanding patterns of emergence and transmission. Pathogens 2016;5:66. DOI: 10.3390/pathogens5040066.
  8. Ortiz JR, Neuzil KM, Rue TC, Zhou H, Shay DK, Cheng PY, et al. Population-based incidence estimates of influenza-associated respiratory failure hospitalizations, 2003 to 2009. Am J Respir Crit Care Med 2013;188(6):710–715. DOI: 10.1164/rccm.201212-2341OC. PMID: 23855650.
  9. Chen X, Liu S, Goraya MU, Maarouf M, Huang S, Chen JL. Host immune response to influenza A virus infection. Front Immunol 2018;9:320. DOI: 10.3389/fimmu.2018.00320.
  10. Teijaro JR, Walsh KB, Cahalan S, Fremgen DM, Roberts E, Scott F, et al. Endothelial cells are central orchestrators of cytokine amplification during influenza virus infection. Cell 2011;146(6):980–991. DOI: 10.1016/j.cell.2011.08.015.
  11. Wang Q, Zhang Y, Wu L, Niu S, Song C, Zhang Z, et al. Structural and functional basis of SARS-CoV-2 entry by using human ACE2. Cell 2020;181(4):894–904. DOI: 10.1016/j.cell.2020.03.045. e9.
  12. Tsatsakis A, Calina D, Falzone L, Petrakis D, Mitrut R, Siokas V, et al. SARS-CoV-2 pathophysiology and its clinical implications: An integrative overview of the pharmacotherapeutic management of COVID-19. Food Chem Toxicol 2020;146:111769. DOI: 10.1016/j.fct.2020.111769.
  13. Said SI, Mutt V. Potent peripheral and splanchnic vasodilator peptide from normal gut. Nature 1970;225: 863–864. DOI: 10.1038/225863a0.
  14. Voice JK, Grinninger C, Kong Y, Bangale Y, Paul S, Goetzl EJ. Roles of vasoactive intestinal peptide (VIP) in the expression of different immune phenotypes by wild-type mice and T cell targeted type II VIP receptor transgenic mice. J Immunol 2003;170:308–314. DOI: 10.4049/jimmunol.170.1.308.
  15. Gonzalez-Rey E, Delgado M. Vasoactive intestinal peptide and regulatory T-cell induction: A new mechanism and therapeutic potential for immune homeostasis. Trends Mol Med 2007;13:241–251. DOI: 10.1016/j.molmed.2007.04.003.
  16. Berisha H, Foda H, Sakakibara H, Trotz M, Pakbaz H, Said SI. Vasoactive intestinal peptide prevents lung injury due to xanthine/xanthine oxidase. Am J Physiol 1990;259:L1515. DOI: 10.1152/ajplung.1990.259.2.L151.
  17. Sharma V, Delgado M, Ganea D. Granzyme B, a new player in activation-induced cell death, is downregulated by vasoactive intestinal peptide in Th2 but not Th1 effectors. J Immunol 2006;176:97110. DOI: 10.4049/jimmunol.176.1.97.
  18. Youssef JG, Zahiruddin F, Al-Saadi M, Yau S, Goodarzi A, Huang HJ, et al. Brief report: Rapid clinical recovery from critical COVID-19 with respiratory failure in a lung transplant patient treated with intravenous vasoactive intestinal peptide. Crit Care Explor 2022;4(1):e0607. DOI: 10.1097/CCE.0000000000000607.
  19. Youssef J, Al-Saadi M, Zahiruddin, Faisal, Beshay, Sarah et al. Rapid recovery from COVID-19 respiratory failure with comorbidity in 21 patients treated with vasoactive intestinal peptide. SSRN Electron J 2020. DOI: 10.2139/ssrn.3679909.
  20. Youssef JG, Lavin P, Schoenfeld DA, Lee RA, Lenhardt R, Park DJ, Fernandez JP, et al. The use of IV vasoactive intestinal peptide (aviptadil) in patients with critical COVID-19 respiratory failure: Results of a 60-day randomized controlled trial. Crit Care Med 2022;50(11):1545–1554. DOI: 10.1097/CCM.0000000000005660.
  21. Brown SM, Barkauskas CE, Grund B, Sharma S, Phillips AN, Leither L, et al. ACTIV-3b/Therapeutics for severely Ill inpatients with COVID-19 (TESICO) study group. Intravenous aviptadil and remdesivir for treatment of COVID-19-associated hypoxaemic respiratory failure in the USA (TESICO): A randomised, placebo-controlled trial. Lancet Respir Med 2023;11(9):791–803. DOI: 10.1016/S2213-2600(23)00147-9.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.